ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 703

Vascular Ischemic Events in Systemic Sclerosis – A Cross-Sectional Comparision with Population-based Controls

Annica Nordin1, Kerstin Jensen-Urstad2, Lena Björnådal3 and Elisabet Svenungsson3, 1Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, 2Department of Clinical Physiology, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden, 3Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Atherosclerosis and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s – Clinical Aspects and Therapeutics

Session Type: Abstract Submissions (ACR)

Background/Purpose:  To investigate the occurrence of ischemic vascular events and subclinical atherosclerosis in patients with systemic sclerosis (SSc) and matched population controls. 

Methods:   111 SSc patients (74% of the patients in Stockholm County) and 105 controls were investigated in this population-based study.  Previous ischemic vascular events were defined as:

  1. Ischemic heart disease (IHD): myocardial infarction (confirmed by electrocardiography and a rise in plasma creatine kinase, muscle and brain fraction (CK-MB) or troponin T) or angina pectoris (confirmed by exercise stress test)
  2. Ischemic cerebral vascular disease (ICVD): cerebral infarction (confirmed by computer tomography) or transitory ischemic attacks (TIA, defined as transient focal symptoms from the brain or retina with a maximum duration of 24 hours),
  3. Ischemic peripheral vascular disease (IPVD): intermittent claudicatio + ankle-brachial index (ABI) < 0.9 or peripheral arterial thrombosis/embolus (confirmed by angiogram or Doppler flow studies).

As measures of subclinical atherosclerosis intima media thickness (IMT) and plaque occurrence was determined with carotid ultrasound and the ABI was calculated. 

Results: Mean age was 62 ± 12 years for patients and controls. In the patient group disease duration was 9.4 (5.6 – 17.4) years, 78% had limited cutaneous systemic sclerosis (lsSSc) and 32% had anti-centromere antibodies (ACA). Ischemic vascular events were more common in the patients (18% vs 7%, p=0.01) due to an increased occurrence of both ischemic heart disease (IHD) and ischemic peripheral vascular disease (IPVD) (12% vs. 4% p=0.03 and 8% vs. 1% p=0.02 respectively). Ischemic cerebral vascular disease was uncommon in both the patient and control group. On a group level frequency of plaques, IMT or ABI did not differ between SSc patients and controls, but the subgroup of patients with ACA had more plaques in comparison both to other SSc patients (67% vs. 39%, p=0.006) and to controls (67% vs. 41%, p=0.02). Patients with ACA also had more ischemic events than other patients (32% vs 11% p=0.01) and controls (32% vs 7% p=0.0003)

 

Patients

(n = 111)

Controls

(n = 105)

Odd Ratio

(95% CI)

P-value

Event % (n)

18 (20)

7 (7)

3.1 (1.2 – 7.6)

0.01

IHD % (n)

12 (13)

4 (4)

3.3  (1.1–10.6)

0.03

ICVD % (n)

3 (4)

3 (3)

0.9 (0.2 – 4.7)

ns

IPVD % (n)

8 (9)

1 (1)

9.2 (1.1 -73.7)

0.02

Plaque % (n)

48 (52)

41 (43)

1.3 (0.7 – 2.3)

ns

 

 

 

b-coefficient

 

IMT mm

0.68 ± 0.13

0.68 ± 0.13

-0.02

ns

ABI

1.13 (1.1–1.2)

1.12 (1.1-1.2)

-0.08

ns

Conclusion: Patients with SSc have more ischemic heart disease and ischemic peripheral vascular disease than controls. The subgroup of SSc patients with ACA seems to be at particularly high risk to develop both ischemic event and premature atherosclerosis. This group should thus be followed closely and vascular prevention considered at an early stage when indicated. The importance to investigate subgroups of well-characterized patients is underscored by this study.


Disclosure:

A. Nordin,
None;

K. Jensen-Urstad,
None;

L. Björnådal,
None;

E. Svenungsson,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/vascular-ischemic-events-in-systemic-sclerosis-a-cross-sectional-comparision-with-population-based-controls/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology